Removal of Duodenum Elicits GLP-1 Secretion

GIOVANNA MUSCOCOGLURI, MD1
TERESA MEZZA, MD1
ANNAMARIA PROIETTA, MD1
GLANIO SORICE, MD1
GENNARO CLEMENTE, MD1
GERARDO SARNO, MD2
GENNARO NUZZO, MD2
ALFREDO PONTECORVI, MD, PHD1
JENS J. HOLST, MD, PHD3
ANDREA GIACCARI, MD, PHD1

OBJECTIVE—To evaluate the effect of removal of the duodenum on the complex interplay between incretins, insulin, and glucagon in nondiabetic subjects.

RESEARCH DESIGN AND METHODS—For evaluation of hormonal secretion and insulin sensitivity, 10 overweight patients without type 2 diabetes (age 61 ± 19.3 years and BMI 27.9 ± 5.3 kg/m²) underwent a mixed-meal test and a hyperinsulinemic-euglycemic clamp before and after pylorus-preserving panrectoduodenectomy for ampulloma.

RESULTS—All patients experienced a reduction in insulin ($P = 0.002$), C-peptide ($P = 0.0002$), and gastric inhibitory peptide (GIP) secretion ($P = 0.0004$), while both fasting and postprandial glucose levels increased ($P = 0.001$). GLP-1 and glucagon responses to the mixed meal increased significantly after surgery ($P = 0.02$ and 0.031). While changes in GIP levels did not correlate with insulin, glucagon, and glucose levels, the increase in GLP-1 secretion was inversely related to the postsurgery decrease in insulin secretion ($R^2 = 0.56; P = 0.012$) but not to the increased glucagon secretion, which correlated inversely with the reduction of insulin ($R^2 = 0.46; P = 0.03$) and C-peptide ($R^2 = 0.37; P = 0.04$). Given that the remaining pancreas presumably has preserved intraislet anatomy, insulin secretory capacity, and α- and β-cell interplay, our data suggest that the increased glucagon secretion is related to decreased systemic insulin.

CONCLUSIONS—Pylorus-preserving panrectoduodenectomy was associated with a decrease in GIP and a remarkable increase in GLP-1 levels, which was not translated into increased insulin secretion. Rather, the hyperinsulinemia may have caused an increase in glucagon secretion.

Bariatric surgery has recently been suggested as a new treatment for type 2 diabetes. After gastric bypass, glycemic improvements in type 2 diabetes occur after few days—long before weight loss. This suggests that mechanisms related to the reconstruction of the gastrointestinal tract and the secretion of gastrointestinal hormones may be responsible for the antidiabetes effect (1). According to Rubino and Marsenaux (2), exclusion of the duodenum provides the key explanation: because of the exclusion, an “anti-incretin factor” is no longer secreted (“the upper gut hypothesis”). Other studies have supported the concept that early exposure of the distal ileum to undigested nutrients (“lower gut hypothesis”) with a subsequent release of antidiabetes hormones gives rise to this phenomenon (1,3–7). Nevertheless, these studies do not rule out that exclusion of the duodenum may contribute to the antidiabetes effects of gastric bypass surgery. In the current study, we examined the effect of duodenum removal in patients undergoing the duodenum pancreatectomy for reasons different from obesity and diabetes. This surgical procedure is associated with a reduction in β-cell mass, which leads to decreasing systemic insulin levels. Since hemipancreatectomy, while lowering insulin levels, is not expected to modify the intraislet relationship between α- and β-cells, we also looked at the relationship between postsurgical insulin and glucagon levels.

RESEARCH DESIGN AND METHODS—A total of 10 patients (6 male and 4 female) undergoing pylorus-preserving panrectoduodenectomy with curative intent at the Hepato-biliary Surgery Unit, Department of Surgery, Agostino Gemelli University Hospital, Rome, Italy, were consecutively enrolled. Indication for surgery was tumor of ampulla of Vater. Pancreatoduodenectomy was carried out according to the pylorus-preserving technique (8). Briefly, the pancreatic head, duodenum, common bile duct, and gallbladder were removed en bloc, leaving a functioning pylorus at the gastric outlet intact. All adjacent lymph nodes were carefully removed. The continuity of the gastrointestinal tract was restored by an end-to-side invaginated pancreaticojejunostomy. Further downstream, an end-to-side hepaticojejunostomy and side-to-side gastroenterostomy or an end-to-end pylorus jejunostomy was made. The pancreas volume removed during the surgery is ~50%, as previously reported by Schrader et al. (9). Figure 1 gives a schematic presentation of the surgical procedure. Only patients with normal cardiopulmonary and kidney functions, as determined by medical history, physical examination, electrocardiography, and urinalysis; without known diabetes; and free of any anti-diabetes medication were enrolled for the studies. Patients were studied 1 week before and after a variable period of recovery from the surgical procedure (a sufficient recovery period was judged on normalization of inflammatory parameters such as C-reactive protein and erythrocytosegmentation rate, stability of weight, and normal diet without any clear symptoms of abnormal intestinal motility or exocrine pancreatic deficiency). The study protocol was approved by the local ethics committee.

From the 1Division of Endocrinology and Metabolic Diseases, Università Cattolica del Sacro Cuore, Rome, Italy; the 2Department of Surgery, Università Cattolica del Sacro Cuore, Rome, Italy; and the 3Novo Nordisk Foundation Center for Basic Metabolic Research, Department of Biomedical Sciences, Panum Institute, University of Copenhagen, Copenhagen, Denmark.

Corresponding author: Giovanna Muscogliuri, giovanna.muscogliuri@gmail.com.

Received 27 April 2012 and accepted 18 November 2012.

DOI: 10.2337/dc12-0811

G.M. and T.M. contributed equally to the manuscript.

© 2013 by the American Diabetes Association. Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. See http://creativecommons.org/licenses/by-nc-nd/3.0/ for details.
Anthropometric parameters were determined according to standard procedures (10). BMI was calculated as weight in kilograms divided by the square of height in meters. All patients had blood samples taken for serum lipid assays (total, HDL, and LDL cholesterol). Blood samples were taken in the morning after an 8-h overnight fast. All the procedures were performed with subjects in a supine position throughout the experiments. The hyperinsulinemic-euglycemic clamp test was performed after a 12-h overnight fast using insulin (40 mU/min/m² body surface) according to the methodology of DeFronzo et al. (11). On the day after, all patients underwent a mixed-meal challenge test using a liquid meal of 830 kcal (107 kcal from protein, 353 kcal from fat, and 360 kcal from carbohydrates) consumed within 15 min. Blood samples were drawn twice in the fasting state and at 30-min intervals over 240 min (time 0, 30', 60', 90', 120', 150', 180', 210', and 240') afterward for the measurement of plasma glucose, insulin, C-peptide, glucagon, glucagon-like peptide-1 (GLP-1), and gastric inhibitory peptide (GIP) concentrations. Blood for glucagon, total GLP-1, and intact GIP was sampled in tubes containing EDTA and a dipeptidyl peptidase-4 inhibitor (Millipore); after centrifugation (1,000 rpm for 10 min at 4°C), they were stored at −80°C until analyzed. Insulin levels were determined using a commercial RIA kit (Medical System; Immulite DPC, Los Angeles, CA). Plasma glucose concentrations were determined by the glucose oxidase technique, using a glucose analyzer (Beckman Instruments, Palo Alto, CA). Plasma C-peptide was measured by autoDELPHIA automatic fluororimmunoassay (Wallac, Turku, Finland), with a detection limit of 17 pmol/L. Immunoreactive glucagon was measured in ethanol-extracted plasma by RIA using antibody code no. 4305 directed against the COOH terminus of glucagon and reacting specifically with pancreatic glucagon (12,13). Total GLP-1 concentrations were measured using antiserum no. 89390, reacting equally with intact GLP-1 (7-36)amide and its primary NH₂-terminally truncated metabolite GLP-1(9-36) amide (14). Intact GIP was measured using antiserum no. 98171, reacting with the NH₂-terminal of GIP but not with the metabolite, GIP 3-42 (15).

**Statistical analysis**

Statistical analysis was carried out using two-way Anova or Student t test, as appropriate, and regression analyses using SPSS version 9 (SPSS, Chicago, IL). The changes in variables during the mixed-meal test were assessed by two-way ANOVA for repeated measures. A post hoc analysis with a two-tailed paired t test was used to assess differences at individual time periods in the study, with Bonferroni correction used for multiple comparisons. A P value of <0.05 was taken to indicate significant differences.

**RESULTS**—The mean ± SD age of patients, six male and four female, was 61 ± 19.3 years (median interval 6; range 22–82), and BMI was 27.9 ± 5.3 kg/m² before and 26.8 ± 3.0 kg/m² after surgery. Table 1 reports metabolic characteristics and mean values of all the measured parameters during the mixed-meal test. Fasting and postchallenge glucose excursion increased after surgery (P = 0.0001) (Fig. 2A), and there was a significant reduction of postprandial insulin levels (P = 0.002) (Fig. 2B) accompanied by a parallel reduction of C-peptide (P < 0.001) (Fig. 2C). In comparison with the preoperative study, the meal ingestion elicited a markedly greater increase in GLP-1 concentrations (P = 0.02) (Fig. 2D) along with a decrease in GIP responses (P < 0.01) (Fig. 2E). We also explored whether the changes in GLP-1, insulin, and glucagon secretion were related after surgery. Interestingly, the greater the increase in the GLP-1 secretion after surgery, the smaller the reduction in insulin secretion (R² = 0.56; P = 0.012) and C-peptide (R² = 0.30; P = 0.04), calculated as percentage of reduction of area under the curve (AUC). While no difference was found in fasting glucagon levels, after surgery glucagon concentrations were higher, particularly 90 min after meal ingestion (P = 0.031) (Fig. 2). The increase correlated with the reduction in insulin as well as C-peptide responses to the meal (individual differences between the preoperative and postoperative AUCs) (R² = 0.46, P = 0.03, and R² = 0.37, P = 0.04, respectively); GLP-1 and glucose AUCs did not correlate with insulin or C-peptide AUCs. GIP AUCs were not related to glucose, insulin, C-peptide, or glucagon levels. No change in insulin sensitivity was found after surgery (glucose uptake changing from 4.27 ± 1.32 to 3.97 ± 1.04 mg·kg⁻¹·min⁻¹, P = 0.44).

**CONCLUSIONS**—As expected because of the pancreas resection, insulin

---

**Table 1—Patients’ anthropometric and metabolic characteristics**

<table>
<thead>
<tr>
<th>Parameters</th>
<th>Before surgery</th>
<th>After surgery</th>
<th>P</th>
</tr>
</thead>
<tbody>
<tr>
<td>BMI (kg/m²)</td>
<td>27.9 ± 5.26</td>
<td>26.8 ± 5.02</td>
<td>0.32</td>
</tr>
<tr>
<td>Fasting glucose (mg/dL)</td>
<td>85.4 ± 7.65</td>
<td>90.7 ± 9.67</td>
<td>0.20</td>
</tr>
<tr>
<td>HbA1c (%)</td>
<td>4.97 ± 0.23</td>
<td>5.44 ± 0.46</td>
<td>0.42</td>
</tr>
<tr>
<td>Insulin (µU/mL)</td>
<td>38.1 ± 18.8</td>
<td>15.0 ± 8.2</td>
<td>0.002</td>
</tr>
<tr>
<td>C-peptide (ng/dL)</td>
<td>8.71 ± 1.77</td>
<td>3.34 ± 1.01</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>GIP (pg/mL)</td>
<td>79.8 ± 34.6</td>
<td>32.2 ± 13.6</td>
<td>0.0004</td>
</tr>
<tr>
<td>GLP-1 (pg/mL)</td>
<td>43.6 ± 13.2</td>
<td>65.2 ± 18.1</td>
<td>0.02</td>
</tr>
<tr>
<td>Glucagon (pg/mL)</td>
<td>12.6 ± 4.10</td>
<td>14.3 ± 5.93</td>
<td>0.031</td>
</tr>
</tbody>
</table>

Data are means ± SD unless otherwise indicated. Mean values (calculated as AUC divided by the meal test duration [240 min]) of glucose, insulin, C-peptide, and incretins during mixed-meal test. P values were calculated using two-way ANOVA for repeated measures.
Figure 2—Plasma concentrations of glucose (A), insulin (B), C-peptide (C), GLP-1 (D), glucagon (E), and GIP (F) in patients examined before and after surgery. At t = 0 min, an oral mixed meal was ingested. Data are presented as means ± SEM. P values were calculated using repeated measures by ANOVA. Significant difference (\( P < 0.05 \)) at individual time points (Bonferroni post hoc test). *Significant (\( P \leq 0.05 \)) differences at individual time points. Increased glucose levels (A) are consequent to decreased insulin and C-peptide levels after surgery (B and C). Incretin adaptation (D and F) to removal of duodenum and consequent reduction of GIP (E). The incretins showed an opposite trend after the surgery, i.e., a major reduction of GIP secretion and increase of GLP-1 release. The rise in glucagon concentration after the removal of duodenum reached the statistical significance after the first hour of the mixed-meal test.
Removal of duodenum elicits GLP-1 secretion

secretion in our patients decreased postoperatively, and this was associated with prolonged postprandial hyperglycemia. Another predictable consequence was a marked decrease in GIP secretion—presumably a direct consequence of the duodenectomy and the shunting of chyme to a site more distally in the jejunum. The GIP-producing K cells are the so-called open type, being able to react to luminal nutrients via their cytoplasmic processes, which are equipped with microvilli protruding into the lumen of the proximal gut (16); therefore, duodenectomy and bypass of the most proximal small intestine probably explain the markedly decreased GIP responses. It is more difficult to explain the increased secretion of GLP-1, which reached levels comparable with those observed after gastric bypass surgery (17). After bypass surgery, the GLP-1 increase is usually explained by delivery of nutrients to regions of the gut where the density of the GLP-1–producing L cells is higher than in the proximal small intestine (18). Since the L cells seem to respond to digested nutrients (monosaccharides, free fatty acids, and amino acids) rather than undigested nutrients (19), the region of origin of the exaggerated secretion is probably the so-called common limb, i.e., the small intestinal segment distal to the entry of the secretory limb carrying the digestive juices. In addition, since there is no retardation of ingested food in the gastric pouch, the passage of nutrients into the distal intestine is very rapid, and this is thought to contribute to the exaggerated secretion of GLP-1 (18,20).

In our patients, the reconstruction of continuity in the gastrointestinal tract after duodenectomy also involves a Roux-en-Y maneuver, but the site of the gastroduodenal-jejunal anastomosis is much more proximal than the entry of the secretory limb after gastric bypass; furthermore, because of the preservation of the stomach plus the pylorus in our patients, there is little or no accelerated gastric emptying. In fact, decelerated emptying has been reported to result from this operation (21,22). In support of this notion, our postprandial glucose levels showed no signs of accelerated gastric emptying, with peak levels actually being reached later after compared with before the operation. Our results are more reminiscent of those obtained after insertion of an endoluminal sleeve (the “endobarrier”), which has a length of only 60 cm and causes increases in GLP-1 secretion and decreases in GIP secretion similar to those observed here (23,24). Interestingly, insertion of an endobarrier is associated with both antidiabetes effects and weight loss. This raises the possibility that bypassing the duodenum/proximal jejunum has beneficial metabolic effects; these may be related to the increasing secretion of GLP-1 but could also lack secretion of a duodenal antidiabetes factor as suggested by Rubino and coworkers (25). The nature of this duodenal factor is unknown, and although GIP has been reported to be able to elicit a neuroendocrine loop resulting in stimulation of GLP-1 secretion in rats (26), a similar mechanism seems unlikely in our patients because of the markedly lowered GIP responses. Recent research has indicated that part of the early GLP-1 response to meal ingestion may derive not from classical ileal or colonic L cells but, rather, from proximal duodenal GLP-1–producing cells, some of which may also express GIP and cholecystokinin (27,28). This is in contrast to the duodenal GIP-expressing cells, which, as a rule, do not express GLP-1. A transfer of nutrients from the duodenum and 60 cm down the small intestine might possibly explain the exaggerated GLP-1 response. At any rate, this response was not associated with concomitant GIP secretion. It may also be noted that the exaggerated GLP-1 response occurred in the face of a decreased GIP response, indicating that under these conditions a mechanism for GLP-1 secretion involving duodenal GIP (or cholecystokinin) is unlikely to be of importance.

Contrasted with gastric bypass operations or insertion of an endobarrier, the partial pancreatectomy in the present operation was associated with impairment of glucose tolerance (although fasting glucose concentrations were not affected). Insulin resistance was also unaltered, so the glucose intolerance is probably best explained by the reduction in insulin secretory capacity, brought about by resection of the head of the pancreas. The secretion of the other pancreatic glucoregulatory hormone, glucagon, did not show a similar reduction, however, but showed a significant elevation after the operation. The so-called intrasilet hypothesis for glucagon secretion assumes that glucagon secretion is regulated by intrasilet levels of insulin in a paracrine manner (29,30). Thus, if insulin secretion falls, glucagon secretion is thought to increase, as it is observed in diabetes with absolute or relative β-cell insufficiency (31). However, in our case the intrasilet hypothesis does not seem to be able to explain the hyperglucagonemia, since the intrasilet relationship between insulin and glucagon would not be expected to change after hemipancreatectomy. However, systemic insulin levels may also influence glucagon secretion, and it remains possible that the subnormal insulin responses observed here may have contributed to the exaggerated glucagon responses observed. Similar arguments were recently presented by Schrader et al. (9) based on studies of glucagon secretion after hemipancreatectomy. In the present studies involving duodenectomy as well, we also have increased GLP-1 levels. Exogenous GLP-1 is a powerful inhibitor of glucagon secretion (32), and blocking of the actions of endogenous GLP-1 is associated with increasing glucagon levels (32,33). It is therefore surprising in our study that glucagon levels increase markedly in the face of elevated GLP-1 levels. However, elevations may be seen after gastric bypass in spite of similarly elevated GLP-1 levels (17), suggesting that similar mechanisms are being activated. One possibility might be secretion of glucagon from the proximal gut. The pro–glucagon-producing L cells of the gut are capable of secreting fully processed glucagon, as demonstrated in patients after total pancreatectomy (34), and given that the stimulus intensity is increased in our patients as well as after gastric bypass, the possibility that the gut is actually the source of the increased glucagon levels cannot be excluded.

In morbidly obese patients with type 2 diabetes, gastric bypass may often cause complete resolution of diabetes, presumably secondary to greatly exaggerated GLP-1 secretion, which is capable of enhancing β-cell function sufficiently to normalize glucose levels (35,36). In support of this notion, GLP-1 secretion was tightly related to insulin secretion (R² = 0.56; P = 0.012). In our patients, there was postoperative glucose intolerance and abnormal, low insulin responses, but nevertheless insulin and GLP-1 responses were correlated, suggesting that without GLP-1 secretion, insulin secretion and therefore diabetes might have been even more impaired.

Our study has several limitations that should be noted. First, this study was performed in patients undergoing both hemipancreatectomy and removal of duodenum; this prevented a “pure” evaluation...
15. Deacon CF, Nauck MA, Meier JJ, Hücking K, Holst JJ. Degradation of endogenous and exogenous gastric inhibitory polypeptide in healthy and in type 2 diabetic

Acknowledgments—This study was supported by grants to A.G. from Università Cattolica del Sacro Cuore (Fondi Ateneo Linea D.3.2 Sindrome Metabolica) and from Fondazione Don Gnocchi. G.M. is the recipient of the Umberto Di Mario Prize by the Società Italiana di Diabetologia 2011.

No potential conflicts of interest relevant to this article were reported.

G.M. and G.P.S. wrote the manuscript. T.M. generated the data. A.Pr. contributed to discussion and reviewed and edited the manuscript. G.C., G.S., and G.N. researched data. A.Po. reviewed and edited the manuscript. J.J.H. generated data and reviewed and edited the manuscript. A.G. reviewed and edited the manuscript. G.M. is the guarantor of this work and, as such, had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.

References


